

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re application of:

Martin OFT

Application No.: Unassigned

Filed: Herewith

For: USES OF IL-23 AGONISTS AND
ANTAGONISTS; RELATED
REAGENTS

Examiner: Unassigned

Art Unit: Unassigned

Conf. No.: Unassigned

"Express Mailing" mailing label number EL 982 851 094US
Date of Deposit: March 9, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

By:



MELANIE LYONS

COMPUTER READABLE SEQUENCE SUBMISSION

Sir:

**Compliance With Requirements For Patent Applications
Containing Nucleotide Sequence And/Or
Amino Acid Sequence Disclosures**

In order to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, for the above-identified application, in accordance with 37 CFR § 1.821 - 1.825, Applicants hereby submit: (1) a write-protected diskette containing a computer-readable submission for the "Sequence Listing"; and (2) a "Sequence Listing" paper copy of the contents of the diskette.

REMARKS

Enclosed is a write protected floppy diskette with the sequence listing generated by the Patent Office's PATENTIN program. The Diskette should comply with the requirements of 37 CFR §1.824 and is IBM PC compatible with a PC-DOS/MS-DOS operating system. If the diskette has been damaged, please call Applicants and a replacement diskette will be provided. A hard paper copy printout of the diskette is attached thereto.

I hereby state the informational contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are believed to be the same. This submission introduces no new matter, since enclosed sequences are the same as sequences which were submitted in priority documents.


Applicants have invested significant labor and care in preparing the present submission. The enclosed items are a bona fide effort to bring the present application into full compliance with the rules for sequence submissions. Should this not be the case, Applicants respectfully request notification of specific deficiencies and an opportunity for remedy, as described in 37 CFR 1.135(c).

Applicants believe that no fees are required; however, if any fees are required by the present Response, the Commissioner is authorized to charge any fees or credit any overpayment to DNAX Research Institute Deposit Account No. 04-1239.

Respectfully submitted,

Date: 09-Mar-2004

By:


Sheela Mohan-Peterson, Reg. No. 41,201
Attorney for Applicants

Customer Number 028008
DNAX Research, Inc.
901 California Avenue
Palo Alto, CA 94304-1104
Telephone (Switchboard): (650) 496-6400
Telephone No. (Direct): (650) 496-1244
Facsimile No.: (650) 496-1200